Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2011 and Provides Update on Development Activities
Date:8/4/2011

andidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unrespectable non-small cell lung cancer. OGX-427 is in Phase 2 clinical development; CSP-9222 and OGX-225 are currently in pre-clinical development.

OncoGenex' Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, such as expected clinical trial initiation and completion dates, patient enrollment targets, proposed amendments to our ongoing clinical trial design and the timing and possibility for approval by the FDA thereof, the timing and costs of our product development activities and the potential benefits of our product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, the risk of delays in our expected clinical trials and the uncertainties regarding patient enrollment rates, the risk that the FDA does not approve our proposed amendment to the Saturn trial design in a timely fashion or at all, the risk that our product candidates do not obtain the requisite regulatory approvals to commercialize, the risk that new developments in the rapidly evolving prostate cancer therapy landscape require additional changes in our clinical trial design or lim
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. OncoGenex Announces Data Highlighting OGX-427 at American Association of Cancer Research (AACR) 102nd Annual Meeting 2011
2. OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
3. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
4. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
5. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
6. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
7. Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results Webcast and Conference Call
8. Visionary Pharmaceuticals, Inc., Announces Initial Seed Round Investments and the Launch of TH17 Autoimmune Disease Research Activities
9. Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division
10. Gamma Pharmaceuticals, Inc. Holds Special Shareholders Meeting
11. Sigma-Tau Pharmaceuticals, Inc. Announces Addition of VP of Finance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Ga. , Oct. 31, 2014  Digirad Corporation ... to PDI, Inc. (Nasdaq: PDII ), a ... of Digirad,s proposal to acquire the company.  ... meaningful discussions regarding a transaction and to operate in ... its cash, or take on additional debt, on acquisitions ...
(Date:10/31/2014)... 31, 2014  Semler Scientific, Inc. (Nasdaq: ... assessment company that develops patented products that assist ... diseases, today reported financial results for the third ... "In the third quarter of ... , M.D., chief executive officer of Semler.  "We ...
(Date:10/31/2014)... , October 31, 2014 Investor-Edge ... MDT ), Abbott Laboratories (NYSE: ABT ... (NYSE: RMD ), and Covidien PLC (NYSE: COV). ... http://investor-edge.com/register . The US markets on Thursday, ... Dow Jones Industrial Average finished at 17,195.42, up 1.30% and ...
Breaking Medicine Technology:Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 2Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 3Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 4Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 5Semler Reports Third Quarter 2014 Financial Results 2Semler Reports Third Quarter 2014 Financial Results 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 2Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 4Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 5
... LAKE, N.J., April 27, 2011 Par Pharmaceutical Companies, Inc. ... settlement in principle to resolve claims brought by the pharmacy ... United States, Texas, and Florida under state and federal law, ... Alaska, South Carolina, and Kentucky under state law for $154 ...
... Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) will be ... on Wednesday, May 4, 2011 at 12:15 p.m. ET ... president, finance and chief financial officer at Amylin Pharmaceuticals, will ... webcast live through the "Investors" section of Amylin,s corporate website ...
Cached Medicine Technology:Par Pharmaceutical Companies Announces Settlement in Principle Regarding Certain Drug Pricing Lawsuits 2
(Date:10/31/2014)... apnea may make it hard for you to remember simple ... your house keys, a small study suggests. Tests on ... -- called spatial memory -- was impaired when sleep apnea ... of sleep weren,t affected. REM sleep is the deepest level ... for the first time that sleep apnea, an increasingly common ...
(Date:10/31/2014)... Hopkins engineers have invented a lab device to give ... complex way that tumor cells spread through the body, ... shedding light on precisely how tumor cells travel, the ... check. , The inventors, from the university,s Whiting School ... details and images from their new system recently in ...
(Date:10/31/2014)... RESEARCH UK scientists have found a drug combination that ... - paving the way for new treatments, according to ... Research Institute (NCRI) Cancer Conference in Liverpool next week*. ... initiate a chain of events culminating in self destruction. ... and become immortal. This means that cells grow out ...
(Date:10/31/2014)... October 31, 2014 Phoenix dentist , ... treatments for November. Whether patients simply need routine care or ... better time than now to get that necessary care. The ... put off routine and even essential treatments due to financial ... substantial savings on any treatments offered by the team at ...
(Date:10/31/2014)... 31, 2014 Adults 65 and ... their Medicare coverage during the current open enrollment ... library for step-by-step guidance, the company announced today. ... on choosing the correct Medicare Advantage plan, understanding ... open enrollment. , “With just one month remaining ...
Breaking Medicine News(10 mins):Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 3Health News:Scientists trigger self-destruct switch in lung cancer cells 2Health News:Phoenix Dentist, Dr. Christy, is Now Offering Ten Percent Off On All Dental Treatments for the Month of November 2
... French . , MONTREAL, December 14, 2010 The first ... to recognize the sound of their parents, voice and the parents ... and newborns admitted to the intensive care unit can be very ... Jan Lariviere, a nurse in the neonatal clinic and the Neonatal ...
... , TUESDAY, Dec. 14 (HealthDay News) -- Most ... United States is funded by states, not the federal government, ... variation in the extent to which states prioritized human embryonic ... in states could likely have been funded under federal government ...
... a woman in New Hampshire have received the first kidney ... Organ Procurement and Transplantation Network (OPTN) that uses a Carnegie ... donors. Both recipients Ken Crowder of St. Louis and ... were willing to donate a kidney but who were medically ...
... (HealthDay News) -- A federal judge ruled Monday that the ... government has no authority to require citizens to buy health ... new legislation, signed into law in March by President Barack ... supporters and opponents of the legislation anticipate the validity of ...
... that alter the activity of genes direct changes to ... control when genes are switched on and off, called epigenetic ... an opening for the cancerous growth of cells. Researchers ... at work on a genome-wide scale in cases of ovarian ...
... HealthDay Reporter , MONDAY, Dec. 13 (HealthDay News) ... may be child,s play, researchers report. A new ... cereals if they,re given a selection of choices at breakfast, ... fruit instead. The 5-to-12-year-olds in the study still ate ...
Cached Medicine News:Health News:Once upon a time in the Intensive Care Unit ... 2Health News:States Now Fund Most Embryonic Stem Cell Research in U.S. 2Health News:2 people receive kidney transplants in pilot program using CMU software 2Health News:2 people receive kidney transplants in pilot program using CMU software 3Health News:Federal Judge Strikes Down Health Reform Law 2Health News:Federal Judge Strikes Down Health Reform Law 3Health News:Ovarian cancer advances when genes are silenced 2Health News:Kids Not So Stuck on Sugary Breakfast Cereals, Study Finds 2Health News:Kids Not So Stuck on Sugary Breakfast Cereals, Study Finds 3
3.5 mm blade. Round handle. Designated most popular model or size....
7 mm curved blade. Round handle....
1.5 mm long blade. Square handle....
Double-ended. 0.9 mm x 1 mm blade. Angled at 90 and 120 degrees. Round handle. Designated most popular model or size....
Medicine Products: